Overview#
Stifel has reiterated its Buy rating on Tango Therapeutics Inc. (NASDAQ:TNGX) and set a price target of $24.00. Currently, the stock is trading at $26.96, which is above the analyst target and close to its 52-week high of $26.81. However, some analyses suggest that the stock may be overvalued compared to its Fair Value.
Combination Therapy Potential#
The firm emphasized the potential of Tango's drug, vopimetostat, when used in combination with RAS(ON) inhibitors. This combination may offer improved treatment durability compared to using either drug alone. While some investors are skeptical about whether this combination truly enhances effectiveness or simply adds benefits, Tango's management insists that there is a synergistic effect.
Recent Developments#
At the upcoming AACR 2026 conference, multiple pre-clinical data points are expected to validate the claims of synergy, as noted by Stifel. The firm has maintained a positive outlook on the combination therapy's potential, which has contributed to a remarkable 1,965% return for the stock over the past year.
Leadership Changes and Financial Performance#
In addition to its drug development efforts, Tango Therapeutics has made significant leadership changes, including the appointment of Matthew Gall as Chief Financial Officer. Gall has prior experience with Kalaris Therapeutics and iTeos Therapeutics. The company is focusing on its PRMT5 inhibitor, vopimetostat, particularly for treating pancreatic cancer. Recently, Tango reported a net loss of $38.7 million for the fourth quarter of 2025 and $101.6 million for the entire year.
Analysts Adjust Price Targets#
Analysts are revising their expectations for Tango Therapeutics. Leerink Partners has raised its price target from $19 to $28, citing increased confidence in the PRMT5 inhibitor program. Stifel also increased its target from $15 to $24 due to developments in the PRMT5 and RAS(ON) combinations. Jefferies has adjusted its target from $14 to $18, pointing out a supply agreement with ERAS for pan-RAS. These changes reflect a more optimistic outlook on the company’s prospects in treating pancreatic ductal adenocarcinoma.